Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 64
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- PharmAbcine
- 16 Oct 2024
- Views366
- 0
- 63
- Press Release
- Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors
- PharmAbcine
- 9 Jul 2024
- Views1389
- 0
- 62
- Press Release
- Press Release PharmAbcine’s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
- PharmAbcine
- 2 Jul 2024
- Views1456
- 0
- 61
- Press Release
- Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
- PharmAbcine
- 23 May 2024
- Views1929
- 0
- 60
- Press Release
- Press Release Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
- PharmAbcine
- 23 Apr 2024
- Views2303
- 0
- 59
- Press Release
- Press Release PharmAbcine Announces Japan Patent Registration for PMC-403
- PharmAbcine
- 29 Feb 2024
- Views2261
- 0
- 58
- Press Release
- Press Release PharmAbcine's PMC-403 Receives FDA Orphan Drug Designation for Idiopathic Systemic Capillary Leak Syndrome
- PharmAbcine
- 20 Feb 2024
- Views1806
- 0
- 57
- Press Release
- Press Release PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
- PharmAbcine
- 24 Jan 2024
- Views2282
- 0
- 56
- Press Release
- Press Release PharmAbcine’s Phase 1 Ophthalmology Program PMC-403 Selected by the KDDF for Government-initiated Drug Development Program
- PharmAbcine
- 6 Dec 2023
- Views2342
- 0